Movement Alert｜Twist Bioscience Corp Pre-Market Rise 5.14%, earnings expectations and Eli Lilly collaboration remain in focus

Market Focus17:06

On November 11, Twist Bioscience Corp rose 5.14% in Pre-Market Trading, trading at $132.13 per share, with turnover of $228.0 million.

The move aligns with continued market focus on the company’s upcoming quarterly results and progress in its collaboration to provide antibody characterization data services for Eli Lilly’s TuneLab platform.

Public market expectations cited ahead of the November 12 earnings release point to quarterly revenue of about $123 million, up 25.96% from a year earlier, while adjusted EPS is expected at a loss of $0.37 to $0.44 per share, with narrowing losses remaining a key point of attention. Broader sentiment has also been supported by a generally positive analyst stance, including an average target price near $150.33, while expectations around AI drug discovery-related orders have contributed to amplified short-term volatility.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment